Iptd-694 -

| Phase | Indication | Design | Status | |-------|------------|--------|--------| | | Healthy volunteers | Double‑blind, placebo‑controlled, 8 dose cohorts (1–100 mg PO) | Completed. Key PK : Cmax reached 2‑3 h, t½ ≈ 7 h, linear PK up to 50 mg. Safety : No serious adverse events (SAEs); mild headache, nausea in ≤10 % of subjects. | | Phase 1b (multiple ascending dose, MAD) | Healthy volunteers | 14‑day repeat dosing (5, 15, 45 mg PO QD) | Completed. PK : Accumulation ratio ~1.7; steady‑state reached day 5. PD : Dose‑dependent reduction of ex‑vivo LPS‑stimulated IL‑1β release (≈45 % at 45 mg). | | Phase 2a (Proof‑of‑Concept) | Mild‑to‑moderate Alzheimer’s disease (AD) | Randomized, double‑blind, 24‑week treatment, 150 participants, 30 mg PO BID vs placebo. Primary endpoint: change in CSF IL‑1β and amyloid‑β PET SUVR. | Ongoing (expected read‑out Q3 2025). Interim data (safety) indicate tolerability similar to placebo; trend toward ↓ CSF IL‑1β (‑30 % vs baseline). | | Phase 2b (Oncology) | Relapsed/refractory AML with NLRP3 over‑expression | Open‑label, dose‑escalation (10‑30 mg

Some potential areas of development in [topic] include: iptd-694

Prepared as of the knowledge cut‑off date (June 2024). All data referenced are from publicly available scientific literature, patents, conference abstracts, and regulatory filings. The compound remains investigational and has not received regulatory approval for any therapeutic indication. | Phase | Indication | Design | Status